Accordingly, targeting FAP by active immunotherapy or T cells engineered to express a FAP-specific CAR decreases tumor growth and this is linked to reduced angiogenesis, changes in extracellular matrix proteins and augmented antitumor immunity [41]. Here, FAP is linked to neoplasm.